Max Mamonkin
@maxmamonkin
Engineering CART for cancer and alloimmunity. Translating to Phase I clinical trials @cagthouston @bcmhouston
ID: 856179633686970368
https://www.bcm.edu/people-search/maksim-mamonkin-26041 23-04-2017 16:15:06
491 Tweet
1,1K Takipçi
289 Takip Edilen
💉 Overcoming T-cell inhibition via the PD-1/PD-L1 axis is a critical challenge in CAR-T cell therapy 📝 Our latest publication in Nature Communications unveils how CAR-antigen affinity could pivotally influence T-cell susceptibility to this axis ⬇️
Safety and anti-tumor activity of autologous Her2 CART in sarcoma. Congratulations Nabil, Meena and the extended team Center for Cell and Gene Therapy and beyond nature.com/articles/s4301…
Excited to share our collaborative work on identifying CART targets for pediatric cancer by exon level expression nature.com/articles/s4146… St. Jude St. Jude Research Nature Portfolio
🚀 Join Our Team at Baylor College of Medicine! 🧬 We’re looking for passionate technician to join our lab at Center for Cell and Gene Therapy. Help us develop innovative and accessible cell therapies for cancer and autoimmunity using genome editing. Pls RT 🙏 jobs.bcm.edu/job/Research-T…
Matt Rea was treated with CD19 CART cells back in 2010 at Baylor Center for Cell and Gene Therapy and has been cancer-free since then, for 14 years. The CAR-T were made from his twin brother. Is he the longest surviving CAR-T patient? blogs.bcm.edu/2024/06/04/fol…
The answer is NO. Here's a patient with neuroblastoma who was treated 18 years ago with GD2.CAR T cells at Baylor Center for Cell and Gene Therapy and still remains in remission. We need more of these stories. researchsquare.com/article/rs-423…
Comprehensive thread highlighting our most recent work now out in Cell Stem Cell describing a novel approach to increase persistence of allogeneic cell therapy products. Work led by amazing Quirin Hammer and Karlo Perica. Precision Immunotherapy Alliance, Oslounivsykehus UiO - Det medisinske fakultet Karolinska Institutet
Congrats to the now Dr. Ruchi Patel for the publication of her PhD thesis in Science Immunology. We show here that CD5 deletion enhances CART immunotherapy in multiple solid and liquid cancer models. Penn Medicine Ruella Lab science.org/doi/10.1126/sc…